Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
- PMID: 35314114
- DOI: 10.1016/j.ejca.2022.01.042
Reply to comment on: Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial
Conflict of interest statement
Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Luis Souhami; Varian Medical Systems – Travel support and honoraria, Abbvie – Board advisor. Abdenour Nabid; The author declares no conflict of interest.
Comment on
-
Androgen deprivation therapy and radiotherapy in intermediate-risk prostate cancer: A randomised phase III trial.Eur J Cancer. 2021 Jan;143:64-74. doi: 10.1016/j.ejca.2020.10.023. Epub 2020 Dec 3. Eur J Cancer. 2021. PMID: 33279855 Clinical Trial.
-
Re: Androgen deprivation therapy and radiotherapy in intermediate risk prostate cancer: A randomized phase III trial.Eur J Cancer. 2022 May;167:164-165. doi: 10.1016/j.ejca.2022.01.041. Epub 2022 Mar 10. Eur J Cancer. 2022. PMID: 35282967 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
